研究者

Our Founding Background

Our founder, Tasuku Okamoto, was engaged in R&D of pharmaceuticals and medical devices in the new business development department of a large company, later becoming an independent entrepreneur involved in the management of a bio-venture company for about 15 years. There, he experienced business successes and failures, including clinical studies for drug discovery and the development of luminescence-molecular imaging of intracellular signal transduction, anti-cancer peptide vaccines, and organ-on-a-chip drug discovery technology. At the same time, he has witnessed the proliferation of biopharmaceuticals and the emergence of new technologies, such as the practical application of genetic screening in cancer care and regenerative medicine.

In this context, he has also faced many medical challenges: 1) the still low chance for patients to encounter the molecularly-targeted drugs they seek in cancer genome medicine, 2) the practical application of regenerative medicine with high developmental hurdles, and 3) the fact that many patients are facing rare diseases for which there is still no known cure.
Now we have successfully developed a technology that can provide a new modality called cell therapy. We are ready to embark once again on the quest for personalized medicine that will allow patients to choose the treatment that best suits their individual needs.

実験装備
細胞コロニー

Company Profile

Company NameOpticell, Inc.
EstablishmentJune 23, 2023
Company PresidentTasuku Okamoto
Share Capital5,500,000 Japanese yen
HeadquartersCross Gate 7th Floor, 1-101-1 Sakuragi-cho Naka-ku, Yokohama, Kanagawa, Japan 231-0062.
Laboratory 1Shonan iPark Laboratory: Open Laboratory in Shonan Health Innovation Park, 2-26-1 Muraoka Higashi, Fujisawa-shi, Kanagawa, 251-8555 Japan
Laboratory 2GeneCare Research Institute Co.,Ltd. Share Laboratory
116-1 Tokiwa, Kamakura, Kanagawa, 248-0022 Japan
Origin of Company Name“Opticell” was born as a unification of the words “optimize” and “cell” to capture the essence of our goals: the best and most efficient utilization of cells.

Founder Message

At Opticell, Inc., our philosophy is to contribute to the advancement of personalized medicine. Through the development of cellular medicine technology, which is expected to be the next generation of medicine, we strive to advance personalized medicine that would allow patients to choose the best treatment for their individual needs.

For example, in the future, we envision the spread of personal cell medicine. In this approach, patients' skin cells are used to create hematopoietic stem cells and neural stem cells. These cells can treat blood and immune disorders and neurological dysfunctions.

In the area of cancer treatment, the development of cancer immuno-cell medicine will be focused on, and the development of immuno-cell medicine that attacks cancer cells by generating T cells from the patient's own skin cells will be challenged.

This time, we have developed a technology that provides a new therapeutic modality: direct cell reprogramming of somatic cells (transdifferentiation), which uses our proprietary peptide technology.

We are now ready to begin realizing personalized medicine, which allows patients to choose the best treatment for their needs.

We look forward to the continued support and cooperation of our stakeholders.

CEO and Founder
Tasuku Okamoto

Career

1984Graduate School of Environmental Science, University of Tsukuba (Master’s Degree)
2007Graduate School of Business Management System Science, University of Tsukuba (MBA)
1984~2007Engaged in R&D and clinical development in the pharmaceutical and medical device business division of Toray Industries, Inc.
2007President of ProbeX, a biopharmaceutical start-up engaged in drug discovery R&D using optical molecular imaging technologies.
2013Founded CREO Bioscience Inc. and worked on organ-on-a-chip drug discovery
2023Founded OptiCell Inc.

Access

Headquarters

Cross Gate 7th Floor, 1-101-1 Sakuragi-cho Naka-ku, Yokohama, Kanagawa, Japan 231-0062

URL https://opticell.co.jp/

Research laboratory

116-1 Tokiwa, Kamakura, Kanagawa, Japan 248-0022
Shared lab facility in GeneCare Research Institute Co., Ltd.